文献速递心力衰竭与心肌病瓣膜病与结构性心脏病

疾病修饰治疗对Vutrisiran在转甲状腺素蛋白心脏淀粉样变性中疗效的影响

Influence of Disease-Modifying Therapy on the Efficacy of Vutrisiran in Transthyretin Cardiac Amyloidosis.
PubMed 文献 · J Am Coll Cardiol · 2026-08-30

HELIOS-B试验的事后分析纳入654例ATTR-CM患者,评估基线及随机后合并使用tafamidis、SGLT2抑制剂、MRA、β受体阻滞剂和RAS抑制剂是否改变Vutrisiran对全因死亡和复发性心血管事件复合终点的疗效。结果显示各药物类别交互作用P值均无统计学意义,提示Vutrisiran疗效在不同当代药物治疗背景下保持一致。

要点

  • 基线时40%患者使用tafamidis,77%使用至少一种心衰药物。
  • 各药物类别与Vutrisiran疗效的交互作用P值均无统计学意义。
  • Vutrisiran疗效在当代ATTR-CM药物治疗谱中保持一致。

核心结论

  • 无统计学显著证据表明tafamidis或心衰治疗改变Vutrisiran对全因死亡和复发性心血管事件的疗效。

研究设计与样本

  • HELIOS-B试验的事后分析,纳入654例随机接受Vutrisiran或安慰剂的ATTR-CM患者。
  • 采用时间更新Lin-Wei-Yang-Ying模型评估复合终点的疗效修饰。

主要发现

  • 基线时40%患者接受tafamidis,77%接受至少一种心衰药物。
  • 随访期间MRA和SGLT2抑制剂是最常新启动的治疗,安慰剂组各心衰药物类别启动率数值上更高。
  • 交互作用P值:tafamidis 0.95,SGLT2抑制剂0.59,MRA 0.92,β受体阻滞剂0.75,ACEI/ARB/ARNI 0.82。

临床怎么用

  • Vutrisiran的疗效不受合并使用tafamidis或心衰药物影响,支持在 contemporary ATTR-CM药物治疗背景下使用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Vutrisiran, an RNA interference therapeutic, reduced all-cause mortality and recurrent cardiovascular events in patients with transthyretin amyloid cardiomyopathy (ATTR-CM) in the HELIOS-B trial. Whether concomitant disease-modifying or heart failure therapy modifies the efficacy of vutrisiran has not been described. OBJECTIVES: We aimed to characterize patterns of concomitant therapy use in HELIOS-B, describe medication initiation rates by treatment arm, and evaluate whether concomitant therapy modified vutrisiran's treatment effect. METHODS: In HELIOS-B, 654 randomized patients with ATTR-CM received vutrisiran or placebo. We assessed baseline use and postrandomization initiation of tafamidis, sodium-glucose cotransporter-2 (SGLT2) inhibitors, mineralocorticoid receptor antagonists (MRA), beta-blockers, and renin-angiotensin system inhibitors (angiotensin-converting enzyme inhibitors/angiotensin receptor blockers/angiotensin receptor-neprilysin inhibitors), and used time-updated Lin-Wei-Yang-Ying models to evaluate treatment effect modification on the primary composite endpoint of all-cause mortality and recurrent cardiovascular events. RESULTS: At baseline, 40% of participants were receiving tafamidis and 77% at least 1 heart failure medication. MRAs and SGLT2 inhibitors were the most frequently initiated therapies during follow-up, with initiation rates numerically higher across all heart failure medication classes in the placebo group. There was no statistically significant evidence that the treatment effect of vutrisiran was modified by baseline or time-updated use of any medication class (P-interaction: tafamidis 0.95, SGLT2 inhibitors 0.59, MRA 0.92, beta-blockers 0.75, angiotensin-converting enzyme inhibitors/angiotensin receptor blockers/angiotensin receptor-neprilysin inhibitors 0.82). CONCLUSIONS: In HELIOS-B, there was no statistically significant evidence that the treatment benefit of vutrisiran on all-cause mortality and recurrent cardiovascular events was modified by concomitant use of tafamidis or heart failure therapies. These findings support the consistency of vutrisiran's efficacy across the spectrum of contemporary ATTR-CM pharmacotherapy. (HELIOS-B: A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy; NCT04153149).

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Abovich A, Fontana M, Claggett B, et al. Influence of Disease-Modifying Therapy on the Efficacy of Vutrisiran in Transthyretin Cardiac Amyloidosis. J Am Coll Cardiol. 2026. PMID: 42669069. doi:10.1016/j.jacc.2026.07.023

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。